Assistant Professor, Oncologic Sciences, USF-Morsani

General Surgery

Pamela J. Hodul, MD practices General Surgery. She studied medicine at Loyola University Chicago Stritch School of Medicine. She received awards:"Fellow". Pamela J. Hodul is a published doctor. She has 29 papers published. The most current publication "Outcomes of resected pancreatic cancer in patients age ≥70." Doctor Pamela J. Hodul, MD is registered with Medicare.

Publications

---

• Outcomes of resected pancreatic Cancer in patients age ≥70.
• Resected pancreatic Cancer outcomes in the elderly.
• Long-term outcomes of inDuction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
• Comparative long-term outcomes of upfront resected pancreatic Cancer after preoperative biliary drainage.
• Familial Gastrointestinal Stromal Tumor Syndrome: Report of 2 Cases With KIT Exon 11 Mutation.
• Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine Tumors: a single-center experience.
• Adjuvant radiotherapy and lymph node dissection in pancreatic Cancer treated with surgery and chemotherapy.
• Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated.
• Vitamin E ?-Tocotrienol Induces p27(Kip1)-Dependent Cell-Cycle Arrest in Pancreatic Cancer Cells via an E2F-1-Dependent Mechanism.
• High-grade dysplasia and adenocarcinoma are frequent in side-branch intraDuctal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound.
• Central pancreatectomy for benign pancreatic lesions.
• Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.
• Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic Cancer.
• RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.
• Biology and treatment of metastatic gastrointestinal neuroendocrine Tumors.
• Aggressive surgical resection in the management of pancreatic neuroendocrine Tumors: when is it indicated?
• Outcomes following resection of pancreatic adenoCarcinoma: 20-year experience at a single institution.
• Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic Cancer.
• TNM staging is obsolete.
• The role of cytoreDuctive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas.
• Octreotide does not prevent postoperative pancreatic fistula or mortality following Pancreaticoduodenectomy.
• The effect of preoperative Biliary stenting on postoperative complications after pancreaticoduodenectomy.
• Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy.
• A comparison of pancreaticogastrostomy and pancreaticojejunostomy following pancreaticoduodenectomy.
• Dimethyl 2-[[2-(methoxycarbonyl)-1-(methoxycarbonylmethyl)pyrrol-4-yl]methylene]propanedioate.
• Age is not a contraindication to pancreaticoduodenectomy.
• Defining a role for endoscopic ultrasound in staging periampullary Tumors.
• Dimethyl (1-methyl-1,3-benzimidazol-5-yl)aminomethylenepropanedioate monohydrate.

Schools

---

• Loyola University Of ChicagoStritch School Of Medicine

• Loyola University Chicago Stritch School Of MedicineSurgery

• Clinical Fellow H Lee Moffitt Cancer Center amp Research InstituteSurgical Oncology

• Research Fellow H Lee Moffitt Cancer Center amp Research InstituteSurgical Oncology

• Bs University Of MichiganNeuropsychology

Procedures Preformed

---

• Adrenalectomy
• Appendectomy, Laparoscopic
• Appendectomy, Open
• Biliary Drainage
• View All

Conditions Treated

---

• Abdominal Pain
• Adrenal Gland Cancer
• Anal and Rectal Cancer
• Anal Fissure
• View All

Doctors Specialties

---

• General Surgery

Accepted Insurances

---

Awards

---

• Fellow

Education

---

• Loyola University
• Loyola University Chicago Stritch School of Medicine

Hospital

---

• H. Lee Moffitt Cancer Center and Research Institute

Drug Facts

---

NPI NUMBER		1134166085
NPPES Provider LastName		HODUL
NPPES Provider FirstName		PAMELA
NPPES Provider ZIPCode		336129416
NPPES Provider State		FL
Specialty Description		Surgical Oncology
Total Claim Count		164.0
Distinct Opioid Count		1.0
Opioid Claim Count		13.0
Percent Opioid Claims		7.93

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1134166085
Last Name Of The Provider	HODUL
First Name Of The Provider	PAMELA
View All

Similar Doctors

---

	Dr. Vanessa L. Prowler, MD
	Dr. Abraham S. Marcadis, MD
	Dr. Meira M. Pernicone, MD This Doctor is OpenDoctor Recommended.
	Dr. Amod Sarnaik, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Sharad I. Patel, MD This Doctor is OpenDoctor Recommended.
	Dr. Larry C. Carey, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Thomas J. Krizek, MD
	Dr. Nasreen A. Vohra, MD This Doctor is OpenDoctor Recommended.
	Dr. Dick R. Smith, MD This Doctor is OpenDoctor Recommended.
	Dr. Kyle B. Potts, MD This Doctor is OpenDoctor Recommended.
	Dr. John P. Leone, MD This Doctor is OpenDoctor Recommended.
	Dr. Livingstone S. Dore Jr., MD
	Dr. Lillian G. Dawes, MD This Doctor is OpenDoctor Recommended.
	Dr. Colleen E. Jakey, MD
	Dr. Cristen N. Litz, MD
	Dr. Jonathan S. Ratcliff, MD This Doctor is OpenDoctor Recommended.
	Dr. Eduardo P. Layug, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog